THE MM-021 CHINA REGISTRATION TRIAL: A PHASE 2 STUDY OF LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE IN CHINESE RELAPSED/REFRACTORY MYELOMA PATIENTS

被引：0
|
作者：
Hou, J. [1 ]
Du, X. [2 ]
Jin, J. [3 ]
Cai, Z. [3 ]
Chen, F. [4 ]
Zhou, D. [5 ]
Yu, L. [6 ]
Ke, X. [7 ]
Li, X. [8 ]
Wu, D. [9 ]
Meng, F. [10 ]
Ai, H. [11 ]
Zhang, J. [12 ]
Chen, N. [12 ]
Mei, J. [12 ]
Wang, J. [13 ]
机构：
[1] Shanghai Changzheng Hosp, Shanghai, Peoples R China
[2] Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
[4] Cent S Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China
[5] Beijing Union Med Coll Hosp, Beijing, Peoples R China
[6] 301 Mil Hosp, Beijing, Peoples R China
[7] Peking Univ, Hosp 3, Beijing, Peoples R China
[8] Shanghai Sixth Peoples Hosp, Shanghai, Peoples R China
[9] Suzhou Univ, Affiliated Hosp 1, Suzhou, Peoples R China
[10] Southern Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China
[11] 307 PLA Hosp, Beijing, Peoples R China
[12] Celgene Corporat, Summit, NJ USA
[13] Changhai Hosp, Shanghai, Peoples R China
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P813
引用
收藏
页码：341 / 341
页数：1
相关论文
共 50 条
  • [41] Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program
    Du, Xin
    Jin, Jie
    Cai, Zhen
    Chen, Fangping
    Zhou, Dao-bin
    Yu, Li
    Ke, Xiaoyan
    Li, Xiao
    Wu, Depei
    Meng, Fanyi
    DeMarco, Dena
    Zhang, Jingshan
    Mei, Jay
    Hou, Jian
    BMC CANCER, 2016, 16
  • [42] Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program
    Xin Du
    Jie Jin
    Zhen Cai
    Fangping Chen
    Dao-bin Zhou
    Li Yu
    Xiaoyan Ke
    Xiao Li
    Depei Wu
    Fanyi Meng
    Dena DeMarco
    Jingshan Zhang
    Jay Mei
    Jian Hou
    BMC Cancer, 16
  • [43] Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): Results of a phase 3 study (MM-010).
    Dimopoulos, MA
    Spencer, A
    Attal, M
    Prince, M
    Harousseau, JL
    Dmoszynska, A
    Yu, ZU
    Olesnyckyj, M
    Zeldis, J
    Knight, R
    BLOOD, 2005, 106 (11) : 6A - 7A
  • [44] Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
    Salcedo, Meghan
    Lendvai, Nikoletta
    Mastey, Donna
    Schlossman, Julia
    Hultcrantz, Malin
    Korde, Neha
    Mailankody, Sham
    Lesokhin, Alexander
    Hassoun, Hani
    Smith, Eric
    Shah, Urvi
    Diab, Victoria
    Werner, Kelly
    Landau, Heather
    Lahoud, Oscar
    Drullinsky, Pamela
    Shah, Gunjan
    Chung, David
    Scordo, Michael
    Giralt, Sergio
    Landgren, Ola
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (03): : 198 - 200
  • [45] A phase lb multicenter dose escalation study of carfilzomib plus lenalidomide and low-dose dexamethasone in relapsed multiple myeloma - preliminary results
    Niesvizky, R.
    Wang, M.
    Bensinger, B.
    Vallone, M.
    Gutierrez, A. A.
    Kauffman, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 569 - 569
  • [46] PEMBROLIZUMAB PLUS LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EFFICACY AND BIOMARKER RESULTS FROM THE PHASE 1 KEYNOTE-023 STUDY
    Otero, P. Rodriguez
    Mateos, M-V.
    Orlowski, R.
    Siegel, D.
    Reece, D.
    Moreau, P.
    Ocio, E. M.
    Munshi, N.
    Avigan, D.
    Ghori, R.
    Wnek, R.
    Mogg, R.
    Marinello, P.
    Miguel, J. San
    HAEMATOLOGICA, 2017, 102 : 319 - 319
  • [47] MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability Of Pomalidomide plus Low-Dose Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment
    Matous, Jeffrey
    Siegel, David S.
    Duong, Hien K.
    Kasserra, Claudia
    Chen, Min
    Doerr, Thomas
    Sternas, Lars
    Zaki, Mohamed H.
    Jacques, Christian
    Shah, Jatin J.
    BLOOD, 2013, 122 (21)
  • [48] Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma
    Jung, Seung-Hyun
    Lee, Sung-Eun
    Lee, Minho
    Kim, So-Hee
    Yim, Seon-Hee
    Kim, Tae Woo
    Min, Chang-Ki
    Chung, Yeun-Jun
    HAEMATOLOGICA, 2017, 102 (11) : E456 - E459
  • [49] Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study
    Mateos, Maria-Victoria
    Orlowski, Robert Z.
    Ocio, Enrique M.
    Rodriguez-Otero, Paula
    Reece, Donna
    Moreau, Philippe
    Munshi, Nikhil
    Avigan, David E.
    Siegel, David S.
    Ghori, Razi
    Farooqui, Mohammed Z. H.
    Marinello, Patricia
    San-Miguel, Jesus
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (05) : E117 - E121
  • [50] Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma
    Zagouri, Flora
    Roussou, Maria
    Kastritis, Efstathios
    Gavriatopoulou, Maria
    Eleutherakis-Papaiakovou, Evangelos
    Kanellias, Nikolaos
    Kalapanida, Despoina
    Christoulas, Dimitrios
    Migkou, Magdalini
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    LEUKEMIA & LYMPHOMA, 2016, 57 (08) : 1776 - 1780
12345